NASHVILLE, Tenn.--(BUSINESS WIRE)--Diagnovus, LLC, a molecular diagnostic company focused on underserved, aggressive and lesser-known diseases, today announced an important addition to its ENGAUGE™ cancer assay portfolio with the launch of the ENGAUGE™-cancer DLBCL Gene Panel, the first commercially available genomic profile to aid physicians in tailoring treatment specifically for patients with diffuse large B-cell lymphoma (DLBCL). The assay is being introduced at the American Society of Hematology Annual Meeting Dec. 7–10, 2013, in New Orleans (Booth #1924).
Help employers find you! Check out all the jobs and post your resume.